Download Free Medical Cardiovascular Disease and The Elderly PowerPoint Presentation

Cardiovascular Disease and The Elderly PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : Check out this medical PowerPoint presentation titled "Cardiovascular Disease and the Elderly” by Dorothy D. Sherwood, MD, FACP.

This medical PowerPoint presentation is about cardiovascular disease in the elderly.

Cardiovascular disease (CVD) is a leading cause of death and disability worldwide, and it is particularly prevalent among the elderly population. As people age, the risk of developing CVD increases, and the disease can have a significant impact on their quality of life.

Cardiovascular disease is a significant health concern for the elderly population. However, with proper prevention, treatment, and management, many individuals can continue to live full and active lives despite the disease.

Tags : cardiovascular disease in the elderly, Geriatrics, Geriatric Medicine, Geriatrics PowerPoint presentation

Published on : May 02, 2023 | Views : 2012 | Downloads : 5

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

Cardiovascular Disease and the Elderly Dorothy D. Sherwood, MD, FACP
Slide 2-

So who are you calling old?
Slide 3-

Introduction The clinical manifestation of CHD in older patients represents the effect of the disease superimposed on the physiological effects of age. At autopsy, 50% of elderly women and 75% of elderly men have obstructive CAD Octogenarians comprise 5% of the US population – but 20% of the hospitalizations for MI. Coronary arteriography- older individuals have worse disease than the younger.
Slide 4-

Clinical Manifestations/Angina Typical angina only 40% have this Dyspnea – this is related to ischemia on a stiff hypertrophied left ventricle raising PA pressure Nausea and vomiting, syncope Secondary MI – post pneumonia, fractured hip. Pulmonary Edema much more common presentation in the elderly Lack of angina based on sedentary life style due to co-morbid conditions.
Slide 5-

Myocardial Infarction in the Elderly Increased mortality due to increase co morbid conditions, more extensive CHD, and lesser use of beneficial therapies. When comparing treatment provided to those over 75 vs. under 75 Thrombolysis – 5% vs. 39% PTCA – 7% vs. 29% CABG- 5% vs. 11% Asa – 57% vs. 82%
Slide 6-

Intervention in the Elderly Octogenarians with unstable angina treated medically have an event-free-one- year survival of 55% Stenting outcomes are similar in the older vs. younger group although some studies show excess non-Q wave MI and vascular complications. CABG – 3 year survival 77% vs. 54% with medical therapy alone; 5 year survival vs. stenting – 66% vs 55% 4.7% mortality rate in octogenarians – but hospital course is prolonged and complicated.
Slide 7-

Management of Risk Factors in the Elderly Smoking Increased Bp Increased Heart Rate Increased PV resistance Increased catecholamines Increased susceptibility to clotting Decreased HDL
Slide 8-

Management of Risk Factors in the Elderly Smoking continued: Cessation reduces mortality by 25 to 50% most MI Interventions: Strong Physician Advice, Support Groups, Pharmacological Therapies, Telephone follow up. Nicotine replacement is safe Cardiac Rehab Program provides the counseling.
Slide 9-

Management of Risk Factors in the Elderly Hypertension Present in >60 % of adults over age 60. Individuals 55 to 65 do no have htn, have a 90% lifetime risk of developing it. Isolated systolic hypertension is the most common in this age group – 60 to 75% of the cases – primarily due to diminished arterial compliance. Threefold increase in risk of MI, LVH, renal dysfunction, stroke and cardiovascular mortality
Slide 10-

Management of Risk Factors in the Elderly ISH CAD risk varies directly with the systolic and pulse pressure and inversely with the diastolic pressure - i.e. worse outcomes in elderly with low diastolic pressure Cardiovascular events can occur if the diastolic pressure is reduced below the level needed to maintain perfusion. Goal should be 65 or > in patients with CAD and 60mm Hg in patients without CAD
Slide 11-

Management of Risk Factors in the Elderly/Hypertension Treatment Efficacy Sodium restriction to 2 grams – usual diet is 4 grams – one tsp of salt is 2 grams. TONE trial in patients form 60 to 80 placed on weight loss diet, salt restricted diet or both – those patients dropped BP 2 to 4 mm Hg systolic and 1 to 2 mm Hg diastolic Not much bang for the buck – and elderly do have trouble with salt restriction. None the less – worth 30 seconds of education at each visit.
Slide 12-

Management of Risk Factors in the Elderly/Hypertension Treatment Efficacy Over 15,693 patients over the age of 60 with systolic hypertension have been studied. Number needed to treat to prevent one major CV event 18 men, 38 women 19 over 70, 39 under 70 16 with prior CV disease, 37 without SHEP trial – attained BP 143/68 with therapy, 155/72 with placebo – stroke 5.5 in treated, 8.2% in placebo, ¼ decrease in cardiac events, and reduced LV mass index.
Slide 13-

Management of Risk Factors in the Elderly/Hypertension Treatment efficacy HYVET trial – all patients over 80 – 3800 patient. - placebo or indapamide ( thiazide diuretic) and perindopril ( ace inhibitor) Fatal stroke – 6.5% vs. 10% Death from all caused – 47.2% vs 59.6% Goal BP in patients over 80 in this study was 150/80
Slide 14-

Management of Risk Factors in the Elderly/Hypertension Choosing the right drug Start low go slow Remember their barro-receptors don’t work so don’t drop them fast. The all get orthostatic – to what degree is important
Slide 15-

Management of Risk Factors in the Elderly/Hypertension Choosing the right drug – continued Diuretics; Angiotensin-converting enzyme (ACE) inhibitors; Calcium channel blockers (CCBs); Angiotensin receptor blockers (ARBs); and Renin Inhibitor Central Alpha Agonist Alpha Blocker Beta-blockers.
Slide 16-

Management of Risk Factors in the Elderly/Hypertesnion Choosing the right drug Most elderly will require combination therapy Most octogenarians do not want diuretics Avoid beta blocker for first line treatment unless otherwise indicated. Consider cost
Slide 17-

Management of Risk Factors in the Elderly/Hypertension Choosing the right drug Low dose combination therapy: 1) greater efficacy; 2) 24-hour efficacy with once-a-day dosing (if the correct combination of drugs is utilized); 3) a greater response rate than monotherapy; 4) fewer side effects than monotherapy; 5) fewer metabolic side effects than monotherapy; and 6) the possibility that the combination drugs result in a lower per patient cost than higher dose monotherapy (
Slide 18-

Management of Risk Factors in the Elderly/Hypertension Choosing the right drug Combination Amolodipine/benazepril (Lotrel) Lisinopril/hydrocholothiazide (Zesoretic) Additions Diuretic or calcium channel blocker to above Further addition Aliskerin ( Tekturna) Beta blocker Central alpha agonist Peripheral alpha blockers.
Slide 19-

Management of Risk Factors in the Elderly/Hypertension Summary Among elderly less than 80, initiate therapy with systolic pressures greater than 140mm Hg and diastolic pressure greater than 90 mm Hg. Among elderly over 80 with ISH – initiate therapy between 150 to 160 systolic and goal should be 150 systolic – avoid diastolic hypotension ( less than 60).
Slide 20-

Management of Risk Factors in the Elderly/Hyperlipidemia Total cholesterol levels increase with age primarily from an increase in the LDL-cholesterol Multiple studies have shown that a high LDL and low HDL in the elderly is associated with significant CHD risk.
Slide 21-

Management of Risk Factors in the Elderly/Hyperlipidemia Benefits of lipid lowering drugs in the elderly 4S trial – simvastatin trial – 1000 patients over 65 – with angina or prior MI – treatment reduced all cause mortality by 34%, mortality from MI by 43% , and revascularization by 41% CARE trial – 1200 patients over 65 – Treatment prevented 225 hospitalizations and 207 events in the elderly; 121 and 150 in the young LIPID trial – treatment with pravastatin – # needed to treat in elderly vs. young to prevent event; 20 to 30 vs. 40 to 70
Slide 22-

Management of Risk Factors in the Elderly/Hyperlipidemia Further studies PROSPER trial – ages 70 to 82 – pravastatin 40 vs. placebo- 5000 participants – Reduction in coronary death and nonfatal MI – but not decrease in all cause mortality SAGE trial – age 65 to 80 – 80 mg atorvastatin vs. 40 mg of pravastatin – decrease in major CV events with intensive therapy and decrease in mortality
Slide 23-

Management of Risk Factors in the Elderly/Hyperlipidemia Barriers to treatment Misconception that benefit of treatment will take years – really is shown in 6 months – improves endothelial dysfunction in days Fear of increased risk of side effects in the elderly ; no studies have shown this – side effects same in the elderly as the young Cost – not issue with generics
Slide 24-

Management of Risk Factors in the Elderly/Hyperlipidemia Primary prevention – limited data on lipid lowering in the aged Greater than 40% of those over 65 meet the NCEP guidelines for treatment There is a 37% incidence of subclinical vascular disease in patients over 65 as measured by EKG, Echo, and AAI ( < 0.9) Over 50% of elderly people will die from Cad The Cardiovascular Health Study 9 patients over age 65 without known heart disease ) did suggest significant benefit from primary prevention in the older population
Slide 25-

Management of Risk Factors in the Elderly/Aspirin Aspirin therapy has been proven to be of greater benefit in the elderly with CAD than in the young. Use it – and use it with PPI – except in the acute setting when clopidogrel is also being used. Aspirin in primary prevention in men is proven – in women, is controversial – weigh risk benefit.
Slide 26-

Management of Risk Factors in the Elderly/ACE inhibitor, Beta Blocker ACE inhibitor and Beta Blockers are effective post MI and should be used. Start with low doses and titrate up. Be alert to side effects based on decreased creatinine clearance and reduced beta receptors.
Slide 27-

Management of Risk Factors in the Elderly/Exercise Benefits: Improvement of exercise tolerance Reduction of symptoms Reduction of cholesterol levels Reduction of cigarette smoking Improvement in psychosocial well-being and reduction of stress Lowering of blood pressure Barriers: Lack of physician Rx, economic, logistics, cost
Slide 28-

Management of Risk Factors in the Elderly/Exercise Diagnosis that qualify for Finley Ewing Cardiac Rehabilitation . Heart attack Atherosclerotic heart disease Angina pectoris Abnormal stress test Valvular heart disease Pacemaker or AICD Heart failure Angioplasty or artherectomy Coronary artery bypass surgery Heart transplant Potential benefits of Cardiac Rehabilitation include:
Slide 29-

Atrial Fibrillation Briefly – elderly benefit most from warfarin anticoagulation. There is no increased serious adverse events in the elderly patient on warfarin vs. high dose aspirin. However, due to co morbid conditions, dementia, inability to monitor INR , recurrent falls, warfarin is often stopped. Evidence supports aspirin and clopidogrel if warfarin cannot be used.
Slide 30-

Atrial Fibrillation If the patient has no symptoms from atrial fibrillation, then rate control only is indicated. If patient is symptomatic with dyspnea, weakness, then trial at cardioversion is indicated.
Slide 31-

Summary If one lives long enough, he or she will die. Our jobs as physicians is to delay that death while life is good. Choose your treatment based on your patient. Be aggressive with the healthy elderly; save the inheritance of the sick. Treat the patient with the care and concern you would treat your mother or father. Be careful, be correct, and be compassionate.